New Thomson Reuters Index reports health care inflation for privately insured; costs climbed 6.3% in year ending 2nd-qtr 2010
The cost of health care for people in the USA with employer-sponsored health insurance climbed an estimated 6.3% for the year ending June 30, according to a new Thomson Reuters index.
The Thomson Reuters Healthcare Spending Index for Private Insurance measures historical and current levels of per capita health care spending for individuals whose coverage is provided by self-insured employers - a segment that represents about 25% of US health care expenditures.
"The index is accurate and detailed because it's based on the healthcare utilization of millions of Americans," said Gary Pickens, chief research officer at the Thomson Reuters Center for Healthcare Analytics. "That allows us to report on cost trends overall and for key components - hospitals, physicians, drugs, and patients' out-of-pocket costs," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze